Ribosomal antibiotics: Contemporary challenges

Tamar Auerbach-Nevo, David Baram, Anat Bashan, Matthew Belousoff, Elinor Breiner, Chen Davidovich, Giuseppe Cimicata, Zohar Eyal, Yehuda Halfon, Miri Krupkin, Donna Matzov, Markus Metz, Mruwat Rufayda, Moshe Peretz, Ophir Pick, Erez Pyetan, Haim Rozenberg, Moran Shalev-Benami, Itai Wekselman, Raz ZarivachElla Zimmerman, Nofar Assis, Joel Bloch, Hadar Israeli, Rinat Kalaora, Lisha Lim, Ofir Sade-Falk, Tal Shapira, Leena Taha-Salaime, Hua Tang, Ada Yonath*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

9 Citations (Scopus)

Abstract

Most ribosomal antibiotics obstruct distinct ribosomal functions. In selected cases, in addition to paralyzing vital ribosomal tasks, some ribosomal antibiotics are involved in cellular regulation. Owing to the global rapid increase in the appearance of multi-drug resistance in pathogenic bacterial strains, and to the extremely slow progress in developing new antibiotics worldwide, it seems that, in addition to the traditional attempts at improving current antibiotics and the intensive screening for additional natural compounds, this field should undergo substantial conceptual revision. Here, we highlight several contemporary issues, including challenging the common preference of broad-range antibiotics; the marginal attention to alterations in the microbiome population resulting from antibiotics usage, and the insufficient awareness of ecological and environmental aspects of antibiotics usage. We also highlight recent advances in the identification of species-specific structural motifs that may be exploited for the design and the creation of novel, environmental friendly, degradable, antibiotic types, with a better distinction between pathogens and useful bacterial species in the microbiome. Thus, these studies are leading towards the design of "pathogen-specific antibiotics," in contrast to the current preference of broad range antibiotics, partially because it requires significant efforts in speeding up the discovery of the unique species motifs as well as the clinical pathogen identification.

Original languageEnglish
Article number24
JournalAntibiotics
Volume5
Issue number3
DOIs
Publication statusPublished - Sept 2016

Funding

We thank Yael Posner, Shoshana Tel-Or, Miriam Lachever, Yaacov Halfon, and Maggie Kessler for experimental support, as well as the staff of beamlines at APS 19ID and 24ID at APS, and ID23-1, ID29, and ID23-2 at ESRF, for their assistance during data collection. Funding was provided by the Adams Foundation (to C.D. and M.K.) and the Clore Foundation (to M.S.B.), the U.S. National Institutes of Health (GM34360), the European Research Council (Grants ERC 322581-NOVRIB and POC 632167-PATRES), the Advanced Merieux Research Grant, and the Kimmelman Center for Macromolecular Assemblies. A.Y. holds the Martin S. and Helen Kimmel Professorial Chair. Publisher Copyright: © 2016 by the authors; licensee MDPI, Basel, Switzerland.

All Science Journal Classification (ASJC) codes

  • General Pharmacology, Toxicology and Pharmaceutics
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)
  • Biochemistry
  • Microbiology

Fingerprint

Dive into the research topics of 'Ribosomal antibiotics: Contemporary challenges'. Together they form a unique fingerprint.

Cite this